進行性遺傳性肝內膽汁淤積症 2 型治療市場：依藥物、通路及地區分類。

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, By Distribution Channel, and By Region

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年，進行遺傳性肝內膽汁淤積症2型的治療市場進行性估計為2.16億美元，預計到2033年將達到22.771億美元。預計從2026年到2033年，該市場將以40.0%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	2.16億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	40.00%	2033年市場規模預測：	22.771億美元

進行性遺傳性肝內膽汁淤積症2型（PFIC2）是一種罕見的肝臟疾病。患者通常在嬰兒期出現徵兆，包括嚴重搔癢、黃疸、門靜脈高壓（肝臟供血靜脈血壓升高）和肝脾腫大（肝臟和脾臟增大）。 PFIC2通常在出生後的最初幾年內進展為肝功能衰竭。患者罹患肝細胞癌（一種肝癌）的風險也較高。 PFIC2是由ABCB11基因突變所引起，並以體染色體隱性遺傳方式遺傳。治療方案包括熊去氧膽酸治療以預防肝損傷、手術和/或肝臟移植。目前已知PFIC有三種：PFIC1、PFIC2和PFIC3。

市場動態

人們對進行性遺傳性肝內膽汁淤積症2型（PFIC2）的認知不斷提高，預計將在不久的將來為PFIC2治療市場的相關人員創造更多機會。例如，2019年10月3日，專注於罕見兒童肝病並致力於開發新型膽汁酸調變器的臨床遺傳性公司Albireo Pharma, Inc.宣布支持“PFIC宣傳日”，進行性其對PFIC患者及其家庭的支持承諾。

然而，儘管中低收入國家的經濟成長加速，但醫療費用支出方面的差距並未解決，全球醫療費用支出不平等現象仍然存在。例如，根據世界衛生組織2015年發布的報告《全民健康納保的全球醫療費用支出新視角》，高所得國家僅佔世界人口的16%，卻佔全球醫療費用支出的80%。相較之下，全球76%的人口居住在中等收入國家，但這些國家的醫療保健支出卻不到全球醫療支出的20%。人口超過5億的低收入國家在2015年的醫療保健支出佔全球醫療保健支出的比例不到1%。因此，低收入國家醫療保健支出不足是限制罕見疾病治療研發的因素。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對全球進行進行性遺傳性肝內膽汁淤積症（II 型）治療市場的主要參與者進行了分析：公司概況、財務業績、產品系列、地理企業發展、分銷策略、關鍵發展和總體戰略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、政府措施、技術升級、市場擴張和行銷策略做出明智的決策。
這份題為《全球進行進行性遺傳性肝內膽汁淤積症 (PFIC) 2 型治療市場》的報告，面向業內廣泛的相關人員，包括投資者、產品製造商、經銷商、供應商、研究和諮詢公司、新參與企業和金融分析師。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

公司簡介
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan Pharmaceuticals, Inc.
- Sanofi SA
- Mylan NV
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals
- Jadeite Medicines Inc.
- Ipsen Pharma
- Analyst's Views

第8章

參考
調查方法

簡介目錄

Product Code: CMI4399

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is estimated to be valued at USD 216.0 Mn in 2026 and is expected to reach USD 2,277.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 40.0% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 216.0 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	40.00%	2033 Value Projection:	USD 2,277.1 Mn

Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare condition that affects the liver. People with this condition generally develop signs and symptoms during infancy, which may include severe itching, jaundice, portal hypertension (high blood pressure in the vein that provides blood to the liver) and hepatosplenomegaly (enlarged liver and spleen). PFIC2 generally progresses to liver failure in the first few years of life. Affected people also have an increased risk of developing hepatocellular carcinoma (a form of liver cancer). PFIC2 is caused by change (mutations) in the ABCB11 gene and is inherited in an autosomal recessive manner. Treatment options include ursodeoxycholic acid therapy to prevent liver damage, surgery, and/or liver transplantation. There are three known types of PFIC: PFIC1, PFIC2, and PFIC3.

Market Dynamics

Increasing awareness about progressive familial intrahepatic cholestasis type 2 disease is expected to provide more opportunities for players in the progressive familial intrahepatic cholestasis type 2 treatment market in the near future. For instance, on October 3, 2019, Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced its support for PFIC Awareness Day and reaffirmed its commitment to patients and families living with progressive familial intrahepatic cholestasis (PFIC).

However, higher economic growth in low- and middle-income countries has not closed the gap in health spending, and global inequity in health spending has remained largely unchanged. For instance, according to a report on 'New Perspectives on Global Health Spending for Universal Health Coverage' by WHO published in 2015, high-income countries with only 16% of the world's population, account for 80% of global health spending. Conversely, 76% of the world's population live in middle-income countries, but these account for less than 20% of global health spending. Low-income countries, with more than half a billion people, accounted for less than 1% of the world's health spending in 2015. Thus, low healthcare spending in low income countries limits such countries for research and development of new drugs for treatment of rare diseases.

Key features of the study:

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global progressive familial intrahepatic cholestasis type 2 treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc. and Mirum Pharmaceuticals
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global progressive familial intrahepatic cholestasis type 2 treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for progressive familial intrahepatic cholestasis type 2 treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug (Revenue, USD Mn, 2021 - 2033)
Ursodeoxycholic acid
Cholestyramine
Rifampicin
Late Stage Pipeline Drugs
Others
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Europe
- By Country:
  - U.K.
  - Germany
  - Italy
  - Spain
  - France
  - Russia
  - Rest of Europe
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Asia Pacific
- By Country:
  - Australia
  - India
  - China
  - Japan
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Company Profiles
Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
AbbVie, Inc.
Glenmark Pharmaceuticals Limited
Par Pharmaceuticals, Inc.
Mylan N. V.
Sanofi S.A.
Novartis International AG
Akorn, Inc.
Albireo Pharma, Inc.
Mirum Pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Recent Trends & Key Developments
Regulatory Scenario
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions and Collaborations

4. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Ursodeoxycholic acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
Cholestyramine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
Rifampicin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends

5. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)

6. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, Y-o-Y Growth By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country/Region, 2021 -2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Glenmark Pharmaceuticals Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Par Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi S.A.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan N.V.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis International AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Akorn, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Albireo Pharma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mirum Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Jadeite Medicines Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Ipsen Pharma
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Analyst's Views